Johnson & Johnson and UnitedHealth Report the Same Morning. Here’s What Matters.

7,821.80−0.02%Dow Jones51,710.30−0.06%Nasdaq 10030,861.60−0.22%Russell 20002,807.63−0.05% S&P 5007,821.80−0.02%Dow Jones51,710.30−0.06%Nasdaq 10030,861.60−0.22%Russell 20002,807.63−0.05% S&P 5007,821.80−0.02%Dow Jones51,710.30−0.06%Nasdaq 10030,861.60−0.22%Russell 20002,807.63−0.05% S&P 5007,821.80−0.02%Dow Jones51,710.30−0.06%Nasdaq 10030,861.60−0.22%Russell 20002,807.63−0.05% S&P 5007,821.80−0.02%Dow Jones51,710.30−0.06%Nasdaq 10030,861.60−0.22%Russell 20002,807.63−0.05% S&P 5007,821.80−0.02%Dow Jones51,710.30−0.06%Nasdaq 10030,861.60−0.22%Russell 20002,807.63−0.05% Investing Johnson & Johnson and UnitedHealth Report the Same Morning. Here’s What Matters. Two healthcare giants drop their third-quarter numbers on the same morning, and what each reveals about drug costs, insurance margins, and guidance ranges will set the tone for the entire sector heading into 2027.

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and UnitedHealth Group (NYSE:UNH) both report third-quarter results before the opening bell on Tuesday, October 13, 2026. One is a drug-and-device maker and the other a managed-care giant, so the morning will test the entire healthcare sector at once.

Johnson & Johnson posts its release at approximately 6:45 a.m. ET and holds its call at 8:30 a.m. ET. UnitedHealth Group’s call starts at 8:00 a.m. ET.

On October 2, Jim Cramer noted that investors are avoiding defensive names: “They don’t want to buy the safety of a J&J, which I still think is what you should be buying here.” The price data shows shares up 26.1% year to date and 36.0% over the past year. The only dip is a 1.8% slide over the past month.

Last quarter, adjusted EPS of $2.90 beat estimates on revenue of $25.31 billion. Innovative Medicine grew 7.8% and MedTech rose 4.5%. Management also raised full-year adjusted EPS guidance to $11.60 to $11.75.

Stelara fell 55.2% on biosimilar competition, while Tremfya rose 72.5%. Expect questions on Firefly Bio, which guidance leaves out, as well as Ottava’s FDA path and Abiomed’s 2% decline. The full-year EPS consensus of $11.0734 falls below the guided range of $11.60 to $11.75.

UnitedHealth shares are up 12.8% year to date but down 1.1% over the past month. Analysts have revised their estimates higher anyway. Third-quarter EPS consensus rose to $4.1495 from $3.7557, 90 days ago.

Second-quarter EPS reached $6.38 as the medical care ratio improved to 86.7% from 89.4%. That figure included $860 million of positive reserve development. Full-year guidance calls for adjusted EPS of $19.50 to $20.00 and a medical care ratio of 88.1%.

Medicare cost trend ran below plan. Commercial trend is running “modestly above 11%,” and management says this pushes full commercial margin recovery past 2027. Medicare Advantage membership has shrunk by 965,000 since year-end. Optum Health revenue fell 5% on about 700,000 fewer value-based care patients.

Drug spending links the two companies. UnitedHealth named specialty and anti-inflammatory drugs among its commercial cost drivers, and that category includes J&J’s immunology franchise. Tremfya growth counts as revenue for J&J and as cost pressure for payers.

Beyond that, the link is thin. J&J’s results depend on launches and patent cliffs. UnitedHealth’s depend on use, pricing, and reserves.

For J&J, look for any change to the $11.60 to $11.75 range, or Stelara erosion worse than 55.2%. For UnitedHealth, check whether the 88.1% medical care ratio target holds and whether commercial trend moves further above 11%. Those four markers will indicate which story is driving the healthcare sector into 2027.

Contact [email protected] for any questions or corrections.

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies. Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL’s BloggingStocks, contributing additional hundreds of articles to the investment community. Trey’s editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel. Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, moderating workshop sessions at regional conventions.

Shares of UnitedHealth Group (NYSE:UNH | UNH Price Prediction) are up 4% at midday Tuesday, trading near $368, while Humana (NYSE:HUM) stock is also up 4% to $233. Both managed care names are extending…

Jim Cramer named five blue-chip stocks the market punished after strong earnings, arguing that millions of investors and billions of dollars got it completely wrong.

UnitedHealth Group (NYSE:UNH | UNH Price Prediction) delivered its most convincing quarter in over a year on April 21, 2026, posting a 9.38% EPS beat and raising full-year guidance, sending shares up 6.96% on…

UnitedHealth Group (NYSE:UNH | UNH Price Prediction) reported fourth-quarter and full-year 2025 earnings this morning that fell slightly short of analyst estimates, while offering guidance for the coming year that indicated a roughly 2%…

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) closed the most recent session at $230.42, up 2.58% on the week as buyers rotated back into defensive healthcare names. Our 24/7 Wall St. price target…

Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's biggest drugs faces a brutal competitive hit.

UnitedHealth Group (NYSE:UNH | UNH Price Prediction) stock is up 9% today, rising from $323.48 to $351.40, after the company delivered a Q1 2026 earnings report that beat expectations and raised its full-year outlook.…

Johnson and Johnson has surged over 54% in a year, cleared a major FDA hurdle, and raised its guidance, yet something about the current setup gives pause before hitting buy.

Coca-Cola (NYSE:KO | KO Price Prediction) closed 2025 with steady organic growth and a 63rd consecutive dividend increase, while Johnson & Johnson (NYSE:JNJ) opened 2026 with accelerating pharmaceutical momentum and its own 64-year dividend…